Ligand Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	12,060	10,406	9,797	8,324	8,151
Other Revenue	-	-0	-0	-0	-
Revenue	12,060	10,406	9,797	8,324	8,151
Revenue Growth (YoY)	15.89%	6.22%	17.69%	2.12%	-
Cost of Revenue	9,328	10,033	6,743	6,283	6,552
Gross Profit	2,731	373.23	3,054	2,042	1,599
Selling, General & Admin	3,652	3,576	1,587	1,037	385.23
Research & Development	1,392	1,226	1,192	409.41	409.22
Other Operating Expenses	131.69	85.43	78.98	40.3	29.76
Operating Expenses	5,590	5,845	3,088	2,005	1,155
Operating Income	-2,859	-5,472	-33.49	36.89	444.77
Interest Expense	-518.42	-384.8	-187.79	-97.34	-86.97
Interest & Investment Income	29.2	0.93	0.79	2.1	1.41
Currency Exchange Gain (Loss)	14.66	18.71	-10.25	1.97	0.05
Other Non Operating Income (Expenses)	-347.75	1,981	-1,012	-18.87	-5.63
EBT Excluding Unusual Items	-3,681	-3,856	-1,243	-75.25	353.63
Gain (Loss) on Sale of Assets	-	1.19	58.51	241.21	-
Pretax Income	-3,681	-3,855	-1,185	165.95	353.63
Income Tax Expense	-	731.96	-321.06	-200.91	-67.29
Net Income	-3,681	-4,587	-863.58	366.86	420.92
Net Income to Common	-3,681	-4,587	-863.58	366.86	420.92
Net Income Growth	-	-	-	-12.84%	-
Shares Outstanding (Basic)	8	7	0	0	0
Shares Outstanding (Diluted)	8	7	0	0	0
Shares Change (YoY)	23.64%	2997.31%	903.51%	8.36%	-
EPS (Basic)	-442.00	-681.00	-3971.01	17654.57	21046.01
EPS (Diluted)	-442.00	-681.00	-3971.01	16928.70	21046.01
EPS Growth	-	-	-	-19.56%	-
Free Cash Flow	-3,983	-4,823	-5,191	-1,910	444.26
Free Cash Flow Per Share	-478.29	-715.99	-23870.71	-88125.04	22213.21
Gross Margin	22.65%	3.59%	31.18%	24.52%	19.62%
Operating Margin	-23.71%	-52.58%	-0.34%	0.44%	5.46%
Profit Margin	-30.52%	-44.08%	-8.82%	4.41%	5.16%
Free Cash Flow Margin	-33.03%	-46.34%	-52.99%	-22.94%	5.45%
EBITDA	-2,531	-5,191	198.99	215.99	557.78
EBITDA Margin	-20.99%	-49.88%	2.03%	2.60%	6.84%
D&A For EBITDA	327.47	280.98	232.48	179.1	113.01
EBIT	-2,859	-5,472	-33.49	36.89	444.77
EBIT Margin	-23.71%	-52.58%	-0.34%	0.44%	5.46%
Advertising Expenses	114.05	332.62	60.69	30.11	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.